Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-F vs Basiliximab for Prevention of IgA Nephropathy Recurrence
NCT02523768Phase 4Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Jan 2011
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of antithymocyte globulin rabbit in IgA nephropathy (IgAN), sponsored by CHU Saint-Etienne. Started Jan 2011; status: terminated.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02523768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523768.